Glutamate Transporter EAAT2: A New Target For The Treatment Of Neurodegenerative Diseases

Citations Over TimeTop 11% of 2012 papers

Abstract

Glutamate is the primary excitatory amino acid neurotransmitter in the CNS. The concentration of glutamate in the synaptic cleft is tightly controlled by interplay between glutamate release and glutamate clearance. Abnormal glutamate release and/or dysfunction of glutamate clearance can cause overstimulation of glutamate receptors and result in neuronal injury known as excitotoxicity. The glial glutamate transporter EAAT2 plays a major role in glutamate clearance. Dysfunction or reduced expression of EAAT2 has been documented in many neurodegenerative diseases. In addition, many studies in animal models of disease indicate that increased EAAT2 expression provides neuronal protection. Here, we summarize these studies and suggest that EAAT2 is a potential target for the prevention of excitotoxicity. EAAT2 can be upregulated by transcriptional or translational activation. We discuss current progress in the search for EAAT2 activators, which is a promising direction for the treatment of neurodegenerative diseases.

Related Papers

• → Ethanol Inhibits NMDA Receptor‐Mediated Excitotoxicity in Rat Primary Neuronal Cultures(1993)119 cited
• → The Identification and Characterization of Excitotoxic Nerve-endings in Alzheimer Disease(2004)37 cited
• → Changes in secondary glutamate release underlie the developmental regulation of excitotoxic neuronal cell death(2005)34 cited
• → Guanosine Prevents against Glutamatergic Excitotoxicity in C. elegans(2019)4 cited
• → Exzitotoxizität im ZNS bei Mausmutanten mit veränderten Glutamatrezeptoren(2005)